A detailed history of China Universal Asset Management Co., Ltd. transactions in Incyte Corp stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 43,138 shares of INCY stock, worth $2.49 Million. This represents 0.32% of its overall portfolio holdings.

Number of Shares
43,138
Previous 43,138 -0.0%
Holding current value
$2.49 Million
Previous $2.46 Million 0.04%
% of portfolio
0.32%
Previous 0.31%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024

BUY
$56.55 - $66.59 $973,791 - $1.15 Million
17,220 Added 66.44%
43,138 $2.46 Million
Q4 2023

May 21, 2024

SELL
$52.16 - $64.19 $898,195 - $1.11 Million
-17,220 Reduced 39.92%
25,918 $1.63 Million
Q4 2023

Jan 23, 2024

BUY
$52.16 - $64.19 $1.05 Million - $1.29 Million
20,174 Added 351.22%
25,918 $1.63 Million
Q3 2023

May 21, 2024

BUY
$57.77 - $65.93 $162,853 - $185,856
2,819 Added 96.38%
5,744 $331,000
Q3 2023

Oct 30, 2023

BUY
$57.77 - $65.93 $162,853 - $185,856
2,819 Added 96.38%
5,744 $332,000
Q2 2023

May 21, 2024

SELL
$60.95 - $75.51 $5,851 - $7,248
-96 Reduced 3.18%
2,925 $182,000
Q2 2023

Jul 27, 2023

SELL
$60.95 - $75.51 $5,851 - $7,248
-96 Reduced 3.18%
2,925 $182,000
Q1 2023

May 21, 2024

BUY
$70.23 - $86.01 $53,445 - $65,453
761 Added 33.67%
3,021 $218,000
Q1 2023

Apr 27, 2023

BUY
$70.23 - $86.01 $53,445 - $65,453
761 Added 33.67%
3,021 $218,000
Q4 2022

May 21, 2024

SELL
$67.18 - $84.11 $2.75 Million - $3.44 Million
-40,878 Reduced 94.76%
2,260 $181,000
Q4 2022

Jan 31, 2023

BUY
$67.18 - $84.11 $11,890 - $14,887
177 Added 8.5%
2,260 $182,000
Q3 2022

Oct 21, 2022

BUY
$66.18 - $82.86 $137,852 - $172,597
2,083 New
2,083 $139,000

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $12.8B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.